ERV3 Inhibitors
ERV3 inhibitors represent a class of chemical compounds specifically designed to attenuate the activity of the endogenous retrovirus group 3 (ERV3) at a molecular level. These inhibitors are characterized by their ability to interfere with the replication and function of ERV3 elements within the human genome. The ERV3 is an endogenous retrovirus that has been integrated into the human DNA, and while it is generally inactive, it has been implicated in various cellular processes. The inhibitors work by targeting the key proteins encoded by the ERV3 sequences, which may include the envelope proteins or other regulatory proteins necessary for the potential mobilization or expression of ERV3. By binding to these proteins or interfering with their transcriptional or translational processes, ERV3 inhibitors effectively reduce the functional activity of these retroviral elements. These compounds often display a high degree of specificity, ensuring minimal off-target effects on other genes or proteins within the cellular milieu.
The mechanism of action of ERV3 inhibitors involves the disruption of the intricate sequence of events that normally facilitate the endogenous retrovirus's contribution to cellular processes. These inhibitors may act through direct binding to the ERV3 proteins, thereby obstructing their proper folding and function. Alternatively, they could prevent the assembly of functional retroviral particles within the cell, which is crucial for the mobilization of these elements. In some cases, inhibitors might block the interaction of ERV3 elements with cellular factors that are essential for the retrovirus's expression or integration into the host genome. This targeted inhibition is crucial to the understanding of ERV3's role within the human genome and the potential effects of its activation or repression. The specificity of ERV3 inhibitors underscores their importance in research focused on unraveling the complexities of endogenous retroviruses and their longstanding coexistence with their human hosts.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that blocks multiple signaling pathways. Inhibits cellular kinases that may phosphorylate ERV3, potentially decreasing ERV3 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphatidylinositol 3-kinase inhibitor. By inhibiting PI3K, LY294002 can reduce Akt signaling, which may indirectly lead to the functional inhibition of ERV3 by affecting downstream signaling pathways that regulate ERV3's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress the mTORC1 signaling pathway. As mTOR is involved in the regulation of protein synthesis and cell growth, rapamycin could lead to decreased ERV3 protein levels by generally reducing protein synthesis. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that blocks the MAPK/ERK pathway, which may be involved in the transcriptional regulation of the ERV3. This blockade would result in decreased ERV3 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor. By inhibiting p38 MAPK, SB203580 could interfere with stress-activated protein kinase pathways, potentially decreasing the expression or activity of ERV3. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A c-Jun N-terminal kinase (JNK) inhibitor. The JNK pathway can regulate various cellular processes including transcription. Inhibiting JNK could lead to a reduction in ERV3 expression. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
A cyclin-dependent kinase inhibitor that may disrupt the cell cycle. By affecting CDKs, alsterpaullone could reduce the transcriptional activity of factors that regulate ERV3 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A specific MEK inhibitor that impairs the MAPK/ERK pathway. By inhibiting MEK, PD98059 could diminish ERK-mediated signaling pathways that may influence ERV3 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor similar to LY294002, wortmannin can lead to the inhibition of the Akt pathway, potentially reducing the activity or expression of ERV3. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A broad-spectrum protein kinase C inhibitor. PKC is implicated in numerous signaling pathways, and its inhibition by Go 6983 could indirectly decrease ERV3 signaling. | ||||||